Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
TransCode Therapeutics Inc. (RNAZ) had Stock-Based Compensation of $0.16M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-12.09M |
|
-- |
|
-- |
|
$3.17M |
|
$-3.17M |
|
$-8.91M |
|
$-12.09M |
|
$-12.09M |
|
$-12.09M |
|
$-12.09M |
|
$-12.09M |
|
$-12.09M |
|
$-3.17M |
|
$-3.12M |
|
0.17M |
|
0.17M |
|
$-70.31 |
|
$-70.31 |
|
| Balance Sheet Financials | |
$13.04M |
|
$0.04M |
|
$0.15M |
|
$13.19M |
|
$2.51M |
|
-- |
|
$0.39M |
|
$2.90M |
|
$10.29M |
|
$10.29M |
|
$10.29M |
|
0.83M |
|
| Cash Flow Statement Financials | |
$-3.10M |
|
-- |
|
$8.85M |
|
$5.81M |
|
$11.57M |
|
$5.76M |
|
|
Stock-Based Compensation |
$0.16M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.20 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-3.10M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-117.42% |
|
-117.42% |
|
-91.60% |
|
-117.42% |
|
$12.35 |
|
$-17.98 |
|
$-17.98 |
|